Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cephalon reports earnings, agrees to settle probes

CEPH reported 3Q07 basic adjusted EPS of $1.08, down from $1.71 in 3Q06. The Street was expecting $0.85. CEPH reported 3Q07 sales of $428.7

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE